Industry Developments

Vaccine development image representing universal mRNA influenza vaccines moving into Phase III registration trials.

on

20 May 2026

Universal seasonal flu vaccines are entering late-stage trials. Discover the regulatory affairs leaders needed to navigate these international registration programmes.

Vaccine development image representing universal mRNA influenza vaccines moving into Phase III registration trials.

on

20 May 2026

Universal seasonal flu vaccines are entering late-stage trials. Discover the regulatory affairs leaders needed to navigate these international registration programmes.

Market Insights

RSA Viewpoints

Conceptual companion diagnostics image representing biomarker-led clinical trial design and risk reduction.

on

27 Jan 2026

Integrating biomarkers early in drug development improves patient stratification and trial success. Sourcing diagnostic leaders who understand drug-diagnostic co-development is key.

Conceptual image of personalised therapeutic development representing scalable regulatory pathways for N-of-1 customised medicines.

on

5 Sept 2025

Truly personalised genomic medicines require bespoke clinical trial designs. We review the regulatory affairs directors capable of establishing novel validation pathways.

Latest posts

Appointment recognises Andy’s decade-long contribution to RSA, including team development, scientific expertise and role in building the firm’s West Coast business.

Appointment recognises Andy’s decade-long contribution to RSA, including team development, scientific expertise and role in building the firm’s West Coast business.

Vaccine development image representing universal mRNA influenza vaccines moving into Phase III registration trials.

on

20 May 2026

Universal seasonal flu vaccines are entering late-stage trials. Discover the regulatory affairs leaders needed to navigate these international registration programmes.

Vaccine development image representing universal mRNA influenza vaccines moving into Phase III registration trials.

Universal seasonal flu vaccines are entering late-stage trials. Discover the regulatory affairs leaders needed to navigate these international registration programmes.

Data-led clinical trial image representing artificial intelligence used to stratify patients for more efficient enrolment.

Using machine learning to identify responsive trial participants reduces patient drop-out and de-risks development timelines. We explore the data-fluent leaders driving this shift.

Data-led clinical trial image representing artificial intelligence used to stratify patients for more efficient enrolment.

Using machine learning to identify responsive trial participants reduces patient drop-out and de-risks development timelines. We explore the data-fluent leaders driving this shift.

Secure Your Next Life Science Leader

Move beyond generic search to provide a data-driven overview of your leadership's impact on clinical acceleration.

100%

Executive Retention ~12mo

5,600

Succesful Appointments

94%

Client Satisfacion Rate

6,800+

Subscribed Leaders & Executives

Life sciences advisory image representing specialist leadership search and clinical sector expertise.

United Kingdom

RSA Consulting Ltd & RSA Interims Ltd

The Gate House, Fretherne Road

Welwyn Garden City

Hertfordshire, AL8 6NS

+44 (0) 203 818 8820

hq@thersagroup.com


RSA Consulting Ltd (Company No: 01803896) and RSA Interims Ltd (Company No: 08433229), both registered in England and Wales.

Germany

RSA Consulting GmbH

Theodor-Heuss-Allee 112

60486 Frankfurt

+49 69 667741-470

hq@thersagroup.com


Represented by Nicholas D. Stephens, Kristian Juergensen


Registered in the Commercial Register (Handelsregister), Registration Court: District Court (Amtsgericht) Frankfurt am Main, Register Number: HRB 73074


German VAT Registration Number: VAT registration number according to § 27a of the German Value Added Tax Act (Umsatzsteuergesetz): DE 814 029 343

Switzerland

RSA AG

Hochbergerstrasse 70

4057 Basel

+41 61 563 0188

hq@thersagroup.com


Represented by Nicholas D. Stephens, Kristian Juergensen, Peter Dahinden


Swiss Register Entry & UID: Registered in the Commercial Register (Handelsregister), UID / Enterprise Identification Number: CHE-109.711.591

Singapore

The RSA Group Pte.Ltd

808 French Road

Kitchener Complex 

#07-163

Singapore 200808

+65 6 294 4588,

hq@thersagroup.com


Company EA Number: 07S5575.

Nicholas D. Stephens EA Registration Number: R1107308.

The RSA Group operates through RSA (Holdings) Ltd and its subsidiaries; RSA Consulting Ltd , RSA Interims Ltd , both registered in England and Wales and RSA Consulting GmbH, RSA AG and The RSA Group Pte.Ltd. Registered Office for RSA Holding is: The Gate House, Fretherne Road, Welwyn Garden City, Hertfordshire, AL8 6NS. The RSA Group is a premier global executive search, interim / fractional leadership and advisory firm specialising exclusively in the Life Sciences sector, dedicated to uniting leadership with innovation-driven organisations to accelerate the discovery and delivery of therapies. Registered with the Information Commissioner’s Office (ICO) in full compliance with the Data Protection Act 2018 and UK GDPR.